Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Non-Current Liabilities (2016 - 2017)

Historic Other Non-Current Liabilities for Viking Therapeutics (VKTX) over the last 3 years, with Q1 2017 value amounting to $47113.0.

  • Viking Therapeutics' Other Non-Current Liabilities fell 7677.81% to $47113.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $47113.0, marking a year-over-year decrease of 7677.81%. This contributed to the annual value of $183611.0 for FY2015, which is N/A changed from last year.
  • Per Viking Therapeutics' latest filing, its Other Non-Current Liabilities stood at $47113.0 for Q1 2017, which was down 7677.81% from $202882.0 recorded in Q1 2016.
  • Viking Therapeutics' Other Non-Current Liabilities' 5-year high stood at $202882.0 during Q1 2016, with a 5-year trough of $47113.0 in Q1 2017.
  • Its 3-year average for Other Non-Current Liabilities is $144535.3, with a median of $183611.0 in 2015.
  • Over the last 5 years, Viking Therapeutics' Other Non-Current Liabilities had its largest YoY gain of 7677.81% in 2017, and its largest YoY loss of 7677.81% in 2017.
  • Quarter analysis of 3 years shows Viking Therapeutics' Other Non-Current Liabilities stood at $183611.0 in 2015, then increased by 10.5% to $202882.0 in 2016, then plummeted by 76.78% to $47113.0 in 2017.
  • Its Other Non-Current Liabilities stands at $47113.0 for Q1 2017, versus $202882.0 for Q1 2016 and $183611.0 for Q4 2015.